Introduction
Psoriasis (Psoriasis) is a chronic inflammatory skin disease characterized by excessive growth of skin keratinocytes and hyperkeratosis of the epidermis. Ointments containing steroids are the main ingredients for controlling psoriasis. The patient's condition will rebound quickly after stopping the medication. The development of new pharmacological strategies is an important drug research and development direction. Previous pathological studies have found that keratinocytes in patients' skin show large amounts of integrin α5β1 before and after the disease occurs. At the same time, the accumulation of fibronectin (Fn; α5β1 receptor) in the dermis is an important pathological mechanism that induces immune abnormalities in psoriasis.
Our cell studies have found that the patented drug (9-mer dF; 9dF) can block Fn/α5β1-induced keratinocyte replication and the production of inflammatory factors. Psoriasis animal models have proven that 9dF can inhibit epidermal hyperplasia and skin inflammation. Therefore, 9dF is an innovative therapeutic agent targeting new drug targets, which can improve the shortcomings of steroid creams.
Features / strengths
1.Fulfill unmet medical need
2.Low Toxicity & potentially systemic application
3. Pre-Clinical animal model close to human pathology
4. Display excellent therapeutic efficacy on dry eye animals
5. In vitro model is available to estimate drug bioactivity
6. No further effort is required to ensure the drug synthesis & quality
Specification in detail
Under development
Seek of partners for business cooperation
